BG Medicine Revenue 2010-2015 | BGMD
BG Medicine revenue from 2010 to 2015. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
| BG Medicine Annual Revenue (Millions of US $) |
|
|---|---|
| 2015 | $2 |
| 2014 | $3 |
| 2013 | $4 |
| 2012 | $3 |
| 2011 | $2 |
| 2010 | $1 |
| 2009 | $8 |
| BG Medicine Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2015-12-31 | $0 |
| 2015-09-30 | $0 |
| 2015-06-30 | $1 |
| 2015-03-31 | $0 |
| 2014-12-31 | $1 |
| 2014-09-30 | $1 |
| 2014-06-30 | $1 |
| 2014-03-31 | $1 |
| 2013-12-31 | $1 |
| 2013-09-30 | $1 |
| 2013-06-30 | $1 |
| 2013-03-31 | $1 |
| 2012-12-31 | $1 |
| 2012-09-30 | $1 |
| 2012-06-30 | $1 |
| 2012-03-31 | $0 |
| 2011-12-31 | $0 |
| 2011-09-30 | $0 |
| 2011-06-30 | $0 |
| 2011-03-31 | $1 |
| 2010-12-31 | $0 |
| 2010-09-30 | $0 |
| 2010-06-30 | $0 |
| 2010-03-31 | $0 |
| 2009-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.000B | $0.000B |
| BG Medicine, Inc. operates as a life sciences company focused on the discovery, development, and commercialization of novel diagnostic tests based on biomarkers. The Company is focused on the development of blood-based tests and other candidates for cardiovascular and other diseases. It seeks partnerships with leading diagnostic laboratory instrument manufacturers for the development and commercialization of its products. BG's product candidates include products for Cardiovascular Disease, Central Nervous System (CNS) and Autoimmune Disorders. BG Medicine, Inc. is headquartered in Waltham, Massachusetts. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $141.273B | 26.50 |
| Elevance Health (ELV) | United States | $94.057B | 12.14 |
| CVS Health (CVS) | United States | $84.883B | 10.55 |
| Cencora (COR) | United States | $56.618B | 20.55 |
| Natera (NTRA) | United States | $21.276B | 0.00 |
| DiDi Global (DIDIY) | China | $19.908B | 30.21 |
| BioMerieux (BMXMF) | France | $15.658B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $12.897B | 0.00 |
| Solventum (SOLV) | United States | $11.572B | 10.79 |
| ICON (ICLR) | Ireland | $11.550B | 10.74 |
| CochLear (CHEOY) | Australia | $11.542B | 0.00 |
| Revvity (RVTY) | United States | $11.153B | 18.83 |
| Doximity (DOCS) | United States | $11.088B | 57.66 |
| Viatris (VTRS) | United States | $10.187B | 3.24 |
| Medpace Holdings (MEDP) | United States | $8.637B | 22.94 |
| Avantor (AVTR) | United States | $8.606B | 12.51 |
| Sonic Healthcare (SKHHY) | Australia | $8.191B | 0.00 |
| HealthEquity (HQY) | United States | $7.908B | 38.90 |
| Charles River Laboratories (CRL) | United States | $5.866B | 11.57 |
| Amplifon S.p.A (AMFPF) | Italy | $4.285B | 22.62 |
| Bausch + Lomb (BLCO) | Canada | $4.018B | 23.69 |
| BrightSpring Health Services (BTSG) | United States | $3.685B | 34.11 |
| Sotera Health (SHC) | United States | $3.667B | 20.84 |
| Alignment Healthcare (ALHC) | United States | $3.063B | 0.00 |
| Surgery Partners (SGRY) | United States | $3.009B | 34.51 |
| Concentras Parent (CON) | United States | $2.767B | 14.39 |
| Organon (OGN) | United States | $2.267B | 2.41 |
| Progyny (PGNY) | United States | $2.005B | 44.15 |
| Ardent Health Partners (ARDT) | United States | $1.880B | 0.00 |
| Premier (PINC) | United States | $1.873B | 11.99 |
| GeneDx Holdings (WGS) | United States | $1.857B | 72.70 |
| GoodRx Holdings (GDRX) | United States | $1.799B | 39.08 |
| Agilon Health (AGL) | United States | $1.702B | 0.00 |
| PACS (PACS) | United States | $1.536B | 0.00 |
| Teladoc Health (TDOC) | United States | $1.254B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.111B | 9.32 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.039B | 0.00 |
| Establishment Labs Holdings (ESTA) | $0.967B | 0.00 | |
| CareDx (CDNA) | United States | $0.845B | 13.19 |
| AMN Healthcare Services Inc (AMN) | United States | $0.759B | 6.01 |
| Embecta (EMBC) | United States | $0.724B | 4.96 |
| Nutex Health (NUTX) | United States | $0.720B | 14.10 |
| QDM (QDMI) | Hong Kong, SAR China | $0.583B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.516B | 13.67 |
| Sonida Senior Living (SNDA) | United States | $0.447B | 0.00 |
| Enhabit (EHAB) | United States | $0.404B | 37.95 |
| InnovAge Holding (INNV) | United States | $0.391B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.375B | 0.00 |
| LifeMD (LFMD) | United States | $0.332B | 0.00 |
| SBC Medicals (SBC) | United States | $0.320B | 0.00 |
| DocGo (DCGO) | United States | $0.240B | 9.79 |
| Oncology Institute (TOI) | United States | $0.200B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.186B | 0.00 |
| Beauty Health (SKIN) | United States | $0.133B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.105B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.090B | 0.00 |
| So-Young (SY) | China | $0.085B | 0.00 |
| OncoCyte (OCX) | United States | $0.084B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.078B | 0.00 |
| Biodesix (BDSX) | United States | $0.069B | 0.00 |
| NeueHealth (NEUE) | United States | $0.060B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.058B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.030B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.025B | 0.00 |
| ModivCare (MODV) | United States | $0.020B | 7.05 |
| KindlyMD (KDLY) | United States | $0.016B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.013B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.012B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.009B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| XWELL (XWEL) | United States | $0.004B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |